中国医学创新Issue(6)：55-58,4.DOI:10.3969/j.issn.1674-4985.2016.06.016
紫杉醇及其衍生物在局部进展期乳腺癌新辅助化疗中的临床疗效分析
Clinical Curative Effect Analysis of Paclitaxel and Its Derivative in Locally Advanced Breast Cancer Patients with Neoadjuvant Chemotherapy
邓江波 1罗伙英 1吴家宝1
作者信息
- 1. 广东省英德市人民医院 广东 英德 513000
- 折叠
摘要
Abstract
Objective:To analyze the clinical efficacy and toxicity of Paclitaxel and its derivative (Docetaxel) combined with Pirarubicin Hydrochloride and Cyclophosphamide in locally advanced breast cancer patients with neoadjuvant chemotherapy.Method:A total of 73 patients with locally advanced breast cancer(ⅡB-ⅢC) who completed the new adjuvant chemotherapy admitted to breast surgery in our hospital were selected and divided into the Paclitaxel group for 29 cases and the Docetaxel group for 44 cases.The two groups were combined with Pirarubicin Hydrochloride and Cyclophosphamide for chemotherapy.Neoadjuvant chemotherapy had foursix cycles,21 days for a course of treatment.The clinical efficacy and toxicity of neoadjuvant chemotherapy between the two groups were observed and compared.Result:After chemotherapy,the clinical complete remission rate and total effective rate of Docetaxel group were 40.91% and 93.18%,which were significantly higher than 17.24% and 72.41% of the Paclitaxel group, the differences were statistically significant(P<0.05).Otherwise, the pathological complete remission rates of Docetaxel group and Paclitaxel group were 31.82% and 31.03% respectively,there was no statistically significant difference(P>0.05).The incidence rates of bone marrow suppression and nausea and vomiting in Docetaxel group were significantly higher than those in the Paclitaxel group, the differences were statistically significant(P<0.05),but there were no statistically significant differences in other toxic side effects between the two groups(P>0.05).Conclusion:The clinical efficacy of Docetaxel combined with Pirarubicin Hydrochloride and Cyclophosphamide in locally advanced breast cancer patients with neoadjuvant chemotherapy is significantly better than Paclitaxel,but the bone marrow suppression and nausea and vomiting of toxicity are obvious,can be prevented and controlled.关键词
多西紫杉醇/紫杉醇/进展期乳腺癌/临床疗效/毒副反应Key words
Docetaxel/Paclitaxel/Locally advanced breast cancer/Clinical efficacy/Toxic side effects引用本文复制引用
邓江波,罗伙英,吴家宝..紫杉醇及其衍生物在局部进展期乳腺癌新辅助化疗中的临床疗效分析[J].中国医学创新,2016,(6):55-58,4.
